

Vitamin D, Blood Pressure, and African Americans: Toward a Unifying Hypothesis

Stephen G. Rostand

The Nephrology Research and Training Center, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

Vitamin D deficiency has increasingly been recognized in the general population and especially in African Americans whose deep skin pigmentation makes vitamin D photosynthesis inefficient. Over the last decade there has been increasing interest in the role that vitamin D deficiency may play in BP modulation because many epidemiologic studies have shown an inverse association between serum vitamin D concentration and BP. There is a high prevalence of vitamin D deficiency in African Americans who also have an increased susceptibility to develop hypertension and its consequences. This paper will review the circumstances leading to vitamin D deficiency in the African American population and will also discuss how vitamin D deficiency can affect the renin-angiotensin system, free radical production, inflammatory processes, and carbohydrate tolerance that in turn influence vascular endothelial function and vascular structure producing increased vascular resistance. It will speculate that the presence of vitamin D deficiency throughout life from its earliest phases may adversely affect the microvasculature in African Americans, thereby playing a major role in the genesis and maintenance of hypertension.

Clin J Am Soc Nephrol 5: 1697–1703, 2010. doi: 10.2215/CJN.02960410

Numerous studies across several disciplines have demonstrated that the vitamin D receptor (VDR) and the 1,α-hydroxylase enzyme are found in many tissues and that VDR activation can modulate a variety of physiologic processes in addition to its classical endocrine effects on calcium and parathyroid hormone (PTH) homeostasis and bone mineralization. This has led to an increasing interest in the possible role of vitamin D, the VDR, and 1,α-hydroxylase in the pathogenesis of a number of disease states. Because the VDR and 1,α-hydroxylase are found in vascular endothelial and smooth muscle cells (VSMC) and because vitamin D deficiency is found to occur frequently in the general population, an association of vitamin D deficiency with cardiovascular disease, renal disease, and hypertension is gaining acceptance. Because it has long been observed that African Americans have a higher prevalence of hypertension when compared with Caucasians and because of their high prevalence of vitamin D deficiency, this paper will focus on the role vitamin D deficiency may play in the pathogenesis and maintenance of hypertension as it relates to people of the African Diaspora. Much of what will be discussed also applies to Caucasians but the consequences affect a greater proportion of African Americans, creating a disproportionate risk.

Vitamin D, Ultraviolet (UVB) Light, and BP

Most Africans and others with deep skin pigmentation live at or near the equator. Compared with those living at more northern or southern latitudes, native Africans and other people of color living near the equator have a lower prevalence of hypertension (1–3). We have demonstrated that for each 10° north or south of the equator BP increases by 2.5 mmHg and hypertension prevalence by 2.5% (1). Because available UVB light decreases progressively at increasing distances from the equator, cutaneous vitamin D photosynthesis is progressively limited (4,5). This is particularly problematic for Africans because their high skin melanin content impairs the efficiency of cutaneous vitamin D photosynthesis and at long distances from high UVB regions this limitation is magnified (6). Thus, studies have reported that when compared with Europeans, Africans and other people of color have a significantly higher prevalence of vitamin D deficiency (7–10). Because BP has been shown to vary inversely with UVB light availability and because people of color have a high prevalence of low circulating levels of 25-hydroxyvitamin D₃ (25(OH)D₃), it has seemed reasonable to speculate that vitamin D deficiency may contribute to their increased prevalence of hypertension. In this regard, these studies (7–10) have reported inverse associations between BP and blood concentrations of 25(OH)D₃ and one (8) has suggested that about half the BP difference noted between African Americans and European Americans could be explained by vitamin D deficiency. Although these statistical associations may suggest causality, they do not prove it. However, a relationship between cutaneous vitamin D photosynthesis and BP has been directly confirmed experimentally by Krause *et al.*

Published online ahead of print. Publication date available at www.cjasn.org.

Correspondence: Dr. Stephen G. Rostand, P.O. Box 264, 1530 3rd Avenue South, Birmingham, AL 35294. Phone: 205-934-2646; Fax: 205-975-6154; E-mail: srostand@uab.edu

who found UVB irradiation not only significantly increased 25(OH)D₃ concentrations but also lowered BP, an effect not seen with exposure to UVA radiation (11). Thus, the question remaining to be answered is by what mechanism(s) do(es) vitamin D deficiency contribute to hypertension risk in African Americans. The answer may lie in the effects of vitamin D deficiency on arteries and arterioles.

Vitamin D and VDR Activation and Microvascular Disease

There is considerable evidence to support the view that hypovitaminosis D may be important in the pathogenesis of vasculopathy that contributes to the development of hypertension in African Americans.

Vitamin D and the Renin-Angiotensin System

Twenty-five years ago Resnick *et al.* (12) demonstrated an inverse association between 25(OH)D₃, 1,25-(OH)₂ vitamin D₃ (1,25(OH)₂D₃), and plasma renin activity in hypertensive patients. More recently, Li *et al.* (13) demonstrated hypertension, increased expression of renin mRNA, and increased angiotensin II (Ang II) in a VDR knockout mouse model. These changes were independent of calcium metabolism and the effects on renin and Ang II were reversed by 1,25(OH)₂D₃ bound to VDR. The BP effect was also reversed with angiotensin-converting enzyme inhibition but not by 1,25(OH)₂D₃ alone. Subsequent studies proved the effect was independent of PTH (14). In other studies, Ang II was shown to increase renal arteriolar tone by stimulating calcium entry and storage in vascular endothelial and smooth muscle cells (15). It may also promote VSMC growth and smaller lumen calibers affecting renal blood flow and renal vascular resistance, changes reversed by angiotensin-converting enzyme inhibition (16). Moreover, hypertension and renin-angiotensin system (RAS) upregulation were also found in 1,α-hydroxylase knockout mice, effects that could be corrected with 1,25(OH)₂D₃ (17).

The stimulatory effect of vitamin D deficiency on RAS may induce BP-independent Ang II-mediated inflammatory responses and vascular growth (18). Ang II upregulates extracellular matrix proteins and promotes fibrosis of VSMC by upregulating TGFβ₁, thereby converting VSMC to myofibroblasts and producing vascular stiffness (19). 1,25(OH)₂D₃ has been shown to suppress these effects by downregulating renin mRNA, by inducing hepatocyte growth factor expression, and by blocking activation of pro-inflammatory transcription factors such as NF-κB (20,21). These findings may relate to vascular changes observed in African Americans for it has been observed that TGFβ₁ is overexpressed in African Americans (22).

Increased Ang II expression may also induce oxidative stress in VSMCs by increasing NAD(P)H oxidase activity, producing reactive oxygen species that can affect a multitude of processes including the following: cell growth and migration, including vascular proliferation and hypertrophy, inflammation and extracellular matrix production, including TGFβ₁, ion channels, and endothelial fibrosis and dysfunction (23,24).

1,25(OH)₂D₃ may also exert its effects on vascular structure

and function independent of the RAS. It has been shown to mediate endothelium-dependent vasodilation by increasing expression of vascular endothelial growth factor that can upregulate endothelial nitric oxide synthase and also stimulate VSMC proliferation (25). 1,25(OH)₂D₃ also produces VSMC vasodilation by stimulation of prostacyclin production (26) and by reducing endothelium-dependent VSMC contractions by reducing influx of calcium into endothelial cells (27).

In experimental studies 1,25(OH)₂D₃ induces osteoblastic differentiation in human and bovine vascular smooth muscle. Active vitamin D also increases calcium uptake in aortic smooth muscles, although this finding is not true in all tissues. However, in humans clinical studies show an inverse association between vascular calcification and 1,25(OH)₂D₃ (28). Thus, increased vascular calcium content may partly explain the inverse association of vascular stiffness with 25(OH)D₃ and 1,25(OH)₂D₃ manifested by increased pulse wave velocity and blunted flow-mediated dilation (29).

Characteristics of Resistance Vessels in African Americans

There are significant differences between African Americans and Caucasians with regard to microvascular structure and function; these include increased systemic and renal vascular resistance and decreased renal blood flow (RBF) (30) that may be attributed to activation of the RAS (31). Attenuated endothelium- and nonendothelium-dependent vasodilation has been noted to be manifested by blunted isoproterenol-mediated vasodilation (32) as well as attenuated flow-mediated and nitroglycerin-induced vasodilation (33). This vascular stiffness has been seen at an early age (34) and may precede the onset of hypertension or else is independent of BP.

Differences in microvascular structure such as retinal arteriolar lumen narrowing (35), intima/media fibrosis, and reduced lumen diameters of renal arterioles are seen more frequently in African Americans than in Caucasians (36–38). These, too, have been found to be independent of BP and are felt to predict future hypertension. These structural and functional changes may contribute to the development of hypertension and to secondary glomerulosclerosis so frequently seen in hypertensive African Americans (38) and may be related to the vascular effects of vitamin D deficiency described above.

Vitamin D, Calcium Homeostasis, and Parathyroid Hormone

The foregoing suggest an independent role for vitamin D and VDR activation on vascular structure and function but in whole animals one cannot ignore the fact the vitamin D deficiency stimulates PTH secretion. Thus, its effects must also be considered. It is known that in African Americans PTH is inversely associated with 25(OH)D₃ and is significantly higher than in Caucasians (39). Although short-term exposure to PTH can produce vasorelaxation, long-term exposure is associated with elevated BP. PTH-induced hypertension may be mediated by increasing intracellular calcium concentration, blunting endothelial function, and stimulating vascular growth. Vitamin D deficiency is associated with blunted intestinal calcium absorption and, together with the tendency for African Americans to

consume less dietary calcium, the attendant reduction in extracellular calcium that doubtless contributes to elevated PTH and may also upregulate expression of inflammatory cytokines while diminishing expression of endothelial nitric oxide synthase (40).

Increased PTH and low vitamin D levels manifested by low plasma 1,25-(OH)₂ vitamin D₃ as well as reduced intestinal calcium absorption have been observed in the spontaneously hypertensive rat (SHR) model (41). In these respects this animal model is similar to the elevated PTH and vitamin D–deficient state observed for African Americans. Parathyroidectomy attenuated the BP rise in the SHR model (42). Unlike vitamin D–deficient states in other studies, in the SHR model infusion of calcitriol increased vascular tone, intracellular calcium, and long-term exposure, leading to modest increases in BP (43). Resnick *et al.* (12) found 1,25(OH)₂D₃ to be inversely associated with plasma renin activity in human subjects with essential hypertension demonstrating a similar relationship that has been observed in the VDR knockout mouse model (13). Plasma 25(OH)D₃ is also inversely associated with BP in the Dahl salt-sensitive strain of rat, a condition similar to the salt-sensitive hypertension seen in African Americans (44).

Vitamin D, Insulin Resistance, and BP

In African Americans, hypertension has been closely associated with non–insulin-dependent diabetes mellitus (NIDDM), a disorder well known to cause microvascular disease. Epidemiologic data show that hypertension and NIDDM occur at significantly higher rates in African Americans than in Caucasians (45). In fact, these two conditions occur together so often there has been considerable interest in finding a common cellular pathogenetic mechanism. Vitamin D deficiency may be such a connection because there is evidence linking vitamin D, parathyroid hormone, and NIDDM. Hyperparathyroidism has been associated with insulin resistance that can be ameliorated by parathyroidectomy (46), and in a study of uremic subjects, 1,25-dihydroxyvitamin D₃ also corrected the insulin resistance and glucose intolerance (47). In this regard also, Chiu *et al.* (48) have demonstrated a significant inverse relationship between serum 25(OH)D₃ concentration and insulin sensitivity, suggesting that vitamin D deficiency is associated with pancreatic β cell dysfunction. Mice made diabetic with streptozotocin (STZ) exhibit increased activity of the RAS and hyperglycemia by itself can also stimulate the synthesis of Ang II (49). Endothelial dysfunction has been found early in NIDDM (50) and treatment with large doses of vitamin D has been shown to significantly improve flow-mediated dilation in the brachial artery and to lower BP (51). In addition, activation of the VDR with 1,25(OH)₂D₃ has been shown to decrease Ang II and inflammatory cytokines in VDR knockout STZ-diabetic mice (49). To the extent these experiments are relevant to human disease, the foregoing suggest upregulation of the RAS and activation of inflammatory cytokines, as described above, may serve as a common mechanism linking vitamin D deficiency, NIDDM, and BP in African Americans. However, at present, the link between vitamin D deficiency, β cell function, and insulin resistance is not well established in African Americans (52,53).

Another important aspect of the association between vitamin D deficiency, insulin resistance, and BP in African Americans relates to the potential effects of vitamin D deficiency on pregnancy, fetal and renal development, and the subsequent development of hypertension. Vitamin D deficiency is associated not only with NIDDM but also with gestational diabetes (54). Studies show a high prevalence of vitamin D deficiency during pregnancy in African American and other women of color that is also associated with lower birth weights and low vitamin D levels in their neonates (55,56). Evidence has accrued from animal studies that hyperglycemia or STZ diabetes occurring during gestation can produce renal dysmorphogenesis, including reduced nephron number that is associated with increased expression of intrarenal angiotensin and NF- κ B signaling (57) and may also cause attenuation of arteriolar caliber (58). Thus, vitamin D deficiency may affect intrauterine nephrogenesis and also fetal size and duration of gestation. Because, in humans, reduced nephron number is thought to result from fetal growth retardation, it has been proposed as a possible mechanism for the development of hypertension and renal disease in African Americans (59). Thus, gestational diabetes induced by vitamin D deficiency may have a role, especially because the number of low birth weight children in African Americans is nearly double that of Caucasians. However, at least one study was unable to document reduced nephron number in African Americans (60). Nevertheless, we found that gestational diabetes, rather than gestational age, low birth weight, or fetal growth retardation, contributed significantly to BP in African American children (61). Thus, these data suggest that alterations in renal development and vascular structure and function begin very early in life, most likely, *in utero*, and may be caused by vitamin D deficiency and its secondary effects. These changes are independent of BP and likely set the stage for the future development of hypertension and its subsequent cardiovascular complications.

Caveats

First, the clinical and preclinical data presented here suggest that vitamin D deficiency has a role in the development and maintenance of hypertension and the metabolic factors that contribute to it in African Americans and other people of color living away from equatorial regions. However, although it is our contention that this group is at increased risk because of their high prevalence of vitamin D deficiency, there are no data to suggest that Caucasians with vitamin D deficiency would be at lesser risk. Second, although studies have shown VDR activation can ameliorate pathogenetic factors contributing to vascular disease, improvement in BP has not been consistently found (62), raising questions about the effectiveness of vitamin D supplementation and the importance of vitamin D deficiency in hypertension. The reasons for this are several. First, because hypertension is a phenotype, it has many underlying causes, of which vitamin D deficiency is but one. Other hormonal, physiologic, dietary, and clinical factors such as the sympathetic nervous system, dietary sodium, calcium, and potassium intake, and obesity also contribute to BP modulation and vascular tone. Second, the doses or forms of the vitamin D preparations

used in treatment studies may not have been appropriate. Moreover, no treatment study has been directed specifically at African Americans. Third, it may be that, at the time vitamin D supplementation was initiated, vascular changes induced by vitamin D deficiency and subsequent hypertension were no longer reversible. Fourth, VDR polymorphisms have been described that can affect the relationship of blood levels of 25(OH)D₃, BP, and target organ damage (63), raising the possibility that such polymorphisms may affect VDR activation and/or its interaction with vitamin D response elements producing variable responses to vitamin D supplementation.

Summary

Despite the above-noted cautions, the body of evidence, accumulated over the last several decades, suggests an important role for vitamin D deficiency in the pathogenesis and maintenance of hypertension in African Americans. We speculate (Fig. 1) that, as a consequence of their displacement from the equator, attenuated cutaneous vitamin D photosynthesis is fur-

ther diminished, leading to a high prevalence of vitamin D deficiency. This in turn may lead to RAS and inflammatory cytokine activation causing vascular endothelial dysfunction and structural changes to the microvasculature, leading to vascular stiffness and increased resistance, changes that have been shown to precede the onset of hypertension and that also may occur very early in life. Vitamin D deficiency may also play an as yet to be defined role in the genesis and maintenance of salt-sensitive hypertension seen often in African Americans. Through its effects on PTH, pancreatic β cell function, and insulin sensitivity, vitamin D deficiency may contribute to the development of insulin resistance and NIDDM and to gestational diabetes that not only may affect microvascular structure in adults but also may affect fetal growth and retard renal development, thus contributing to the number of functioning nephrons and to vascular changes *in utero*. These changes may predispose also to the development of glomerulosclerosis, thus to fewer functioning nephrons, and together with altered microvasculature may blunt pressure natriuresis, thereby contrib-




Figure 1. Proposed role for hypovitaminosis D in the genesis and maintenance of elevated BP in African Americans.

uting to sodium retention and salt sensitivity that characterize hypertension in African Americans. Thus, vitamin D deficiency, because of its high prevalence in African Americans beginning at an early age, perhaps even *in utero*, and persisting throughout life may produce changes in large and small arteries and arterioles, creating conditions that may be the basis for the increased risk of African Americans for hypertension and cardio-renal disease. Long-term studies examining the effects of vitamin D supplementation on BP and vascular function in African Americans would be important and are sorely needed.

Acknowledgments

I would like to thank Drs. Anupam Agarwal and David Warnock for their continued support and Dr. Paul Sanders for his helpful comments and suggestions. Mr. David Fischer made the illustration.

Disclosures

This presentation was part of a symposium on “Selective Vitamin D Receptor Activation and the Cardio-Renal Syndrome,” which was held on March 12 through 13, 2010, in Paris. The symposium was supported by an unrestricted educational grant from the Abbott Pharmaceutical Company; Dr. Rostand received travel support and a speaker fee for participation in the symposium. Abbott Pharmaceutical Company had no role in the preparation or review of this manuscript.

References

- Rostand SG: Ultraviolet light may contribute to geographic and racial blood pressure differences. *Hypertension* 30: 150–156, 1997
- Cooper R, Rotimi C, Ataman S, McGee D, Osotimehin B, Kadiri S, Muna W, Kingue S, Fraser H, Forrester T, Bennett F, Wilks R: The prevalence of hypertension in seven populations of west African origin. *Am J Public Health* 87: 160–168, 1997
- Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasani RS: Vitamin D deficiency and risk of cardiovascular disease. *Circulation* 117: 503–511, 2008
- Webb AR, Kline L, Holick MF: Influence of season and latitude on the cutaneous synthesis of vitamin D₃: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D₃ synthesis in human skin. *J Clin Endocrinol Metab* 67: 373–378, 1988
- Diffey BL: Solar ultraviolet radiation effects on biological systems. *Phys Med Biol* 36: 299–328, 1991
- Holick MF: Photosynthesis of vitamin D in the skin: Effect of environmental and life-style variables. *Fed Proc* 46: 1876–1882, 1987
- Nesby-O’Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Dougherty C, Gunter EW, Bowman BA: Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988–1994. *Am J Clin Nutr* 76: 187–192, 2002
- Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. *Am J Hypertens* 20: 713–719, 2007
- Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. *Hypertension* 49: 1063–1069, 2007
- Schmitz KJ, Skinner HG, Bautista LE, Fingerlin TE, Langefeld CD, Hicks PJ, Haffner SM, Bryer-Ash M, Wagenknecht LE, Bowden DW, Norris JM, Engelman CD: Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. *Am J Hypertens* 22: 867–870, 2009
- Krause R, Buhning M, Hopfenmuller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. *Lancet* 352: 709–710, 1998
- Resnick LM, Muller FB, Laragh JH: Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. *Ann Intern Med* 105: 649–654, 1986
- Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 110: 229–238, 2002
- Kong J, Qiao G, Zhang Z, Liu SQ, Li YC: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. *Kidney Int* 74: 1577–1581, 2008
- Conger JD, Falk SA, Robinette JB: Angiotensin II-induced changes in smooth muscle calcium in rat renal arterioles. *J Am Soc Nephrol* 3: 1792–1803, 1993
- Notoya M, Nakamura M, Mizojiri K: Effects of lisinopril on the structure of renal arterioles. *Hypertension* 27: 364–370, 1996
- Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D: Calcium-independent and 1,25(OH)₂D₃-dependent regulation of the renin-angiotensin system in 1 α -hydroxylase knockout mice. *Kidney Int* 74: 170–179, 2008
- Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft FC: Blood pressure-independent effects in rats with human renin and angiotensinogen genes. *Hypertension* 35: 587–594, 2000
- Sorescu D: Smad3 mediates angiotensin II- and TGF- β 1-induced vascular fibrosis: Smad3 thickens the plot. *Circ Res* 98: 988–989, 2006
- Li Y, Spataro BC, Yang J, Dai C, Liu Y: 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. *Kidney Int* 68: 1500–1510, 2005
- Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, Kong J, Li YC: 1,25-Dihydroxyvitamin D₃ targeting of NF- κ B suppresses high glucose-induced MCP-1 expression in mesangial cells. *Kidney Int* 72: 193–201, 2007
- Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P: Transforming growth factor- β 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. *Proc Natl Acad Sci U S A* 97: 3479–3484, 2000
- Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ: NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. *Arterioscler Thromb Vasc Biol* 23: 776–782, 2003
- Sachse A, Wolf G: Angiotensin II-induced reactive oxygen species and the kidney. *J Am Soc Nephrol* 18: 2439–2446, 2007

25. Cardús A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM: 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. *Kidney Int* 69: 1377–1384, 2006
26. Wakasugi M, Noguchi T, Inoue M, Kazama Y, Tawata M, Kanemaru Y, Onaya T: Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. *Prostaglandins* 42: 127–136, 1991
27. Wong MS, Delansorne R, Man RY, Vanhoutte PM: Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. *Am J Physiol Heart Circ Physiol* 295: H289–H296, 2008
28. Hsu JJ, Tintut Y, Demer LL: Vitamin D and osteogenic differentiation in the artery wall. *Clin J Am Soc Nephrol* 3: 1542–1547, 2008
29. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F: Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. *J Am Soc Nephrol* 18: 613–620, 2007
30. Frohlich ED: Hemodynamic differences between black patients and white patients with essential hypertension. State of the art lecture. *Hypertension* 15: 675–680, 1990
31. Price DA, Fisher ND, Osei SY, Lansang MC, Hollenberg NK: Renal perfusion and function in healthy African Americans. *Kidney Int* 59: 1037–1043, 2001
32. Lang CC, Stein CM, Brown RM, Deegan R, Nelson R, He HB, Wood M, Wood AJ: Attenuation of isoproterenol-mediated vasodilatation in blacks. *N Engl J Med* 333: 155–160, 1995
33. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA: Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. *J Am Coll Cardiol* 40: 754–760, 2002
34. Riley WA, Freedman DS, Higgs NA, Barnes RW, Zinkgraf SA, Berenson GS: Decreased arterial elasticity associated with cardiovascular disease risk factors in the young. Bogalusa Heart Study. *Arteriosclerosis* 6: 378–386, 1986
35. Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, Hubbard LD, Sharrett AR: Racial differences in the prevalence of hypertensive retinopathy. *Hypertension* 41: 1086–1091, 2003
36. Tracy RE, Berenson G, Wattigney W, Barrett TJ: The evolution of benign arterionephrosclerosis from age 6 to 70 years. *Am J Pathol* 136: 429–439, 1990
37. Marcantoni C, Ma LJ, Federspiel C, Fogo AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. *Kidney Int* 62: 172–180, 2002
38. Rostand SG, Cross SK, Kirk KA, Lee JY, Kuhlmann A, Amann K: Racial differences in renal arteriolar structure in children with minimal change nephropathy. *Kidney Int* 68: 1154–1160, 2005
39. Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary J: Evidence for alteration of the vitamin D-endocrine system in blacks. *J Clin Invest* 76: 470–473, 1985
40. Talmor-Barkan Y, Rashid G, Weintal I, Green J, Bernheim J, Benchetrit S: Low extracellular Ca²⁺: A mediator of endothelial inflammation. *Nephrol Dial Transplant* 24: 3306–3312, 2009
41. Lucas PA, Brown RC, Drueke T, Lacour B, Metz JA, McCarron DA: Abnormal vitamin D metabolism, intestinal calcium transport, and bone calcium status in the spontaneously hypertensive rat compared with its genetic control. *J Clin Invest* 78: 221–227, 1986
42. Merke J, Lucas PA, Szabo A, Cournot-Witmer G, Mall G, Bouillon R, Drueke T, Mann J, Ritz E: Hyperparathyroidism and abnormal calcitriol metabolism in the spontaneously hypertensive rat. *Hypertension* 13: 233–242, 1989
43. Bukoski RD, Li J, Bo J: Effect of long-term administration of 1,25 (OH)₂ vitamin D3 on blood pressure and resistance artery contractility in the spontaneously hypertensive rat. *Am J Hypertens* 6: 944–950, 1993
44. Thierry-Palmer M, Carlyle KS, Williams MD, Tewolde T, Caines-McKenzie S, Bayorh MA, Emmett NL, Harris-Hooker SA, Sanford GL, Williams EF: Plasma 25-hydroxyvitamin D concentrations are inversely associated with blood pressure of Dahl salt-sensitive rats. *J Steroid Biochem Mol Biol* 66: 255–261, 1998
45. Trends in the prevalence and incidence of self-reported diabetes mellitus – United States, 1980–1994. *MMWR Morb Mortal Wkly Rep* 46: 1014–1018, 1997
46. Kim H, Kalkhoff RK, Costrini NV, Cerletty JM, Jacobson M: Plasma insulin disturbances in primary hyperparathyroidism. *J Clin Invest* 50: 2596–2605, 1971
47. Mak RH: 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. *Kidney Int* 53: 1353–1357, 1998
48. Chiu KC, Chu A, Go VL, Saad MF: Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr* 79: 820–825, 2004
49. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC: Renoprotective role of the vitamin D receptor in diabetic nephropathy. *Kidney Int* 73: 163–171, 2008
50. Coen D, Stehouwer A: Endothelial dysfunction in diabetic nephropathy: State of the art and potential significance for non-diabetic renal disease. *Nephrol Dial Transplant* 19: 778–781, 2004
51. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD: Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. *Diabet Med* 25: 320–325, 2008
52. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. *Diabetes Care* 27: 2813–2818, 2004
53. Ashraf A, Alvarez J, Saenz K, Gower B, McCormick K, Franklin F: Threshold for effects of vitamin D deficiency on glucose metabolism in obese female African-American adolescents. *J Clin Endocrinol Metab* 94: 3200–3206, 2009
54. Zhang C, Qiu C, Hu FB, David RM, van Dam RM, Bralley A, Williams MA: Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. *PLoS One* 3: e3753, 2008
55. Lee JM, Smith JR, Philipp BL, Chen TC, Mathieu J, Holick MF: Vitamin D deficiency in a healthy group of mothers and newborn infants. *Clin Pediatr (Phila)* 46: 42–44, 2007
56. Bowyer L, Catling-Paull C, Diamond T, Homer C, Davis G, Craig ME: Vitamin D, PTH and calcium levels in pregnant women and their neonates. *Clin Endocrinol (Oxf)* 70: 372–377, 2009
57. Tran S, Chen YW, Chenier I, Chan JS, Quaggin S, Hebert MJ, Ingelfinger JR, Zhang SL: Maternal diabetes modulates

- renal morphogenesis in offspring. *J Am Soc Nephrol* 19: 943–952, 2008
58. Mitchell P, Liew G, Rochtchina E, Wang JJ, Robaei D, Cheung N, Wong TY: Evidence of arteriolar narrowing in low-birth-weight children. *Circulation* 118: 518–524, 2008
 59. Lopes AA, Port FK: The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. *Am J Kidney Dis* 25: 350–356, 1995
 60. Hughson MD, Douglas-Denton R, Bertram JF, Hoy WE: Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. *Kidney Int* 69: 671–678, 2006
 61. Rostand SG, Cliver SP, Goldenberg RL: Racial disparities in the association of foetal growth retardation to childhood blood pressure. *Nephrol Dial Transplant* 20: 1592–1597, 2005
 62. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC: Vitamin D intake and risk of incident hypertension: Results from three large prospective cohort studies. *Hypertension* 46: 676–682, 2005
 63. Kulah E, Dursun A, Acikgoz S, Can M, Kargi S, Ilikhan S, Bozdogan S: The relationship of target organ damage and 24-hour ambulatory blood pressure monitoring with vitamin D receptor gene fok-I polymorphism in essential hypertension. *Kidney Blood Press Res* 29: 344–350, 2006